Breaking News
The U.S. Food and Drug Administration (FDA) has granted full approval for Moderna’s Spikevax (mRNA-1273) COVID vaccine in children 6 months through 11 years who are at an increased risk of the disease.
Results of a Dana-Farber Cancer Institute-initiated Phase I clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible and improves the vaccine-specific immune response compared to previous trials of the platform.
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
BioTrending
- By Rachel Maier, MS
While traditional vaccines teach the immune system to fight off foreign invaders, inverse vaccines teach the immune system to ignore its own cells — and may completely reverse autoimmune disease.
- By Keith Berman, MPH, MBA
SHORTAGES AND recent spikes in egg prices have boosted public awareness that a “bird flu” is devastating domestic poultry flocks across the country. Since its arrival in the U.S. in January 2022, more than 166 million farmed poultry animals have been sacrificed in an attempt to control the spread of H5N1, a highly pathogenic avian influenza A (HPAI) featuring H5 hemagglutinin and N1 neuraminidase surface proteins (H5N1).
- By Ronale Tucker Rhodes, MS
The dire projection of physician shortages in the U.S. could cause major problems for both patients and healthcare facilities. What's being done to fix it?
- By Amy Scanlin, MS
The incidence and prevalence of STIs remain high, and the serious health consequences of contracting one make prevention a national imperative.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
